Home / Technology & Devices (page 40)

Technology & Devices

FDA Approves New Mobile Device Monitoring System for Diabetes

NEW YORK, Dec. 2, 2015 /PRNewswire/ — Philosys, the maker of Gmate® products, announced today that the U.S. Food and Drug Administration (FDA) has approved clearance for the Gmate SMART Blood Glucose Monitoring System and App for Android™. The Gmate SMART is a small, portable blood glucose meter that plugs into …

Read More »

Pfizer Enters GPCR-Based Therapy Deal with Heptares

TOKYO–(BUSINESS WIRE)–Sosei Group Corporation (“Sosei”) (TOKYO:4565) today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas. Heptares will …

Read More »

More than a GPO – Premier’s efforts in transforming healthcare

While Premier, Inc. is widely known for operating one of the nation’s largest group purchasing organizations (GPOs) by volume, many may be unaware of the additional suite of valuable services that the company provides to its members to improve the health of communities. Premier is a leading healthcare performance improvement …

Read More »

SkylineDx Receives CE-IVD Mark for its Gene Signature-Based Test for Multiple Myeloma

ROTTERDAM, Netherlands and LAGUNA HILLS, Calif., Nov. 25, 2015 /PRNewswire/ — SkylineDx, today announced they have received CE-IVD registration from the European Competent Authority (Ministry of Health) for the MMprofiler™, the company’s prognostic test to determine the level of risk of a patient with multiple myeloma (MM). SkylineDx is an emerging …

Read More »

Mallinckrodt Pharmaceuticals Receives FDA Clearance For INOmax DS(IR) Plus MRI Device

CHESTERFIELD, United Kingdom, Nov. 16, 2015 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared INOmax DSIR® Plus MRI device for delivery of INOMAX® (nitric oxide) for inhalation during MRI procedures. The INOmax DSIR Plus MRI …

Read More »

Exact Imaging Introduces Prostate Risk Identification Protocol

BARCELONA, Spain and TORONTO, Nov. 12, 2015 /CNW/ – Exact Imaging (www.exactimaging.com), the world’s leader in high–resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance of the prostate, today introduces PRI-MUS™, the first Prostate Risk Identification Protocol using Micro-Ultrasound. This new protocol, the first of its kind in prostate ultrasound, aims …

Read More »

Morphotek Enters License Agreement with Blaze Bioscience for Novel Oncology Imaging Technology

EXTON, Pa., Nov. 9, 2015 /PRNewswire/ — Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of Seattle, WA, a privately held biotechnology company developing Tumor Paint technology.  Under the agreement, Morphotek provides to Blaze an exclusive, worldwide, royalty-bearing …

Read More »

Natera’s mmPCR Technology Successfully Identified breast Cancer in Study

SAN CARLOS, Calif., Oct. 28, 2015 /PRNewswire/ — Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a study published in the October 2015 issue of Translational Oncology showing that Natera’s massively multiplexed PCR (mmPCR) technology and proprietary analytic methodologies can detect …

Read More »

Vertex Pays $105 Million to CRISPR Therapeutics for Gene Editing Technology

BOSTON & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics today announced that the two companies have entered into a strategic research collaboration focused on the use of CRISPR’s gene editing technology, known as CRISPR-Cas9, to discover and develop potential new treatments aimed at the underlying genetic causes …

Read More »